Armata Pharmaceuticals (ARMP) Depreciation & Amortization (CF) (2013 - 2026)

Armata Pharmaceuticals has reported Depreciation & Amortization (CF) for 14 years, with the latest figure at $500000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 32.63% year-over-year to $500000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 20.36% YoY) and the FY2025 annual result came in at $1.5 million, up 15.55% from the prior year.
• Depreciation & Amortization (CF) climbed to $500000.0 in Q1 2026 per ARMP's latest filing, from $431000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $500000.0 in Q1 2026 and troughed at $200000.0 in Q1 2022.
• A 5-year average of $305058.8 and a median of $313000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) plunged 33.33% in 2022, then surged 41.63% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $245000.0 in 2022, then increased by 19.59% to $293000.0 in 2023, then gained by 29.69% to $380000.0 in 2024, then advanced by 13.42% to $431000.0 in 2025, then advanced by 16.01% to $500000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $500000.0, $431000.0, and $370000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.